Adalvo announces its DCP submission for Tacrolimus 0.03% and 0.1% Ointment, a complex, difficult-to-develop formulation designed for effective delivery, and enhancing patient accessibility. With approval anticipated for 2026, this development is set for an early market launch in key European markets.
Manufactured through a European supply chain, Tacrolimus Ointment is indicated for the treatment of atopic dermatitis and achieved global MAT 2023 sales of $332 million and a 3Y CAGR of 1%, according to IQVIA.
Adalvo’s strategic vision ensures we remain ahead of the curve, providing partners with access to competitive, first-to-market products in high-demand therapeutic areas.
Partner up now!